After a good third quarter: Bayer confirms Group outlook
- Details
- Category: Bayer
Sales of the Bayer Group rose by 1.0 percent in the third quarter to EUR 8,670 million (Q3 2010: EUR 8,581 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 4.8 percent.
Bristol-Myers Squibb Delivers Strong Third Quarter
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced double-digit net sales growth in a quarter highlighted by important new data on ELIQUIS ® for stroke prevention in patients with atrial fibrillation and continued investment in external innovation with several strategic transactions.
AstraZeneca Third Quarter Results
- Details
- Category: AstraZeneca
AstraZeneca's Revenue in the third quarter was down 2 percent at CER, but was up 4 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue performance was impacted by government price interventions and the loss of more than $350 million in revenue to generic competition.
Amgen's Third Quarter Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the third quarter of 2011 to $3,944 million versus $3,816 million in the third quarter of 2010. Total product sales increased 3 percent in the third quarter of 2011 to $3,877 million versus $3,759 million in the third quarter of 2010.
GSK delivers strong Q3 performance with underlying sales growth
- Details
- Category: GlaxoSmithKline
The breadth and mix of GSK's product and geographic portfolio is helping the Group to mitigate economic volatility. In the quarter, underlying and reported sales grew 6% and 3% respectively, reflecting growth across all three areas of our business - Pharmaceuticals, Vaccines and Consumer Healthcare.
Merck Total Revenues Increase by 4% to € 2.5 Billion
- Details
- Category: Merck Group
Total revenues of the Merck Group increased 3.8% to € 2,532 million in the third quarter from € 2,438 million in the year-ago quarter with solid contributions from the Pharmaceuticals divisions and the Merck Millipore life science division.
Novartis achieves strong third quarter financial performance and pipeline progress
- Details
- Category: Novartis
Novartis' net sales rose 18% (+12% cc) to USD 14.8 billion in the third quarter. Sales were up mainly due to a strong performance from recently launched products, which contributed USD 3.6 billion or 25% to total net sales for the Group and grew 31% over the previous-year quarter.
More Pharma News ...
- Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
- AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
- Lilly Reports Third-Quarter 2011 Results
- Abbott Reports Strong Ongoing Third Quarter Results
- Bristol-Myers Squibb Announces Changes in Senior Management Team
- Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
- Roche reports positive study of Herceptin given by subcutaneous injection